samedan logo
 
 
 
spacer
home > ebr > spring 2021 > presenting the fluidity one-w serum
PUBLICATIONS
European Biopharmaceutical Review

Presenting the Fluidity One-W Serum

What Does the Fluidity One-W Serum Do?

The Fluidity One-W Serum is able to provide in-solution affinity profiling directly in complex backgrounds, such as minimally diluted serum and cell lysate, as well as buffers to independently determine antibody affinity and concentration.

The Fluidity One W Serum allows researchers, clinicians and biopharma companies to perform novel in solution immunoassays which can independently determine antibody affinity (antibody binding strength) and concentration directly in patient serum. Traditional immunoassays such as ELISAs combine affinity and concentration into a single, less-precise measure known as titer, which cannot readily distinguish between large numbers of weakbinding antibodies and small numbers of strong-binding antibodies. This difference could have major implications for plasma transfer treatments, vaccine and therapeutic development, and the ongoing monitoring of immunity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments, and maintain our personal wellbeing.

To learn more about how our instruments are giving researchers the crucial information they need, you can click here: www.fluidic.com/fluidity-one-w-serum

To request a demo and try out the Fluidity One-W Serum in your lab, click here: www.fluidic.com/demo
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement